

#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MARGEL et al.

Atty. Ref.: 4110-40

Serial No. 10/534,469

TC/A.U.: To be assigned

Filed: May 11, 2005

Examiner: To be assigned

For: BIOLOGICAL GLUE BASED ON THROMBIN-CONJUGATED
NANOPARTICLES

* * * * *

November 16, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of the reference(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

☒ This Information Disclosure Statement ("IDS") is being filed within three (3) months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

☒ This application was filed after June 30, 2003 so that copies of U.S. Patent Publications are not required and are not attached.

☐ This IDS is being filed more than three (3) months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

☐ a. I hereby certify that each item of information contained in this IDS was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this IDS. 37 C.F.R. 1.97(e)(1).

☐ b. I hereby certify that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. 1.97(e)(2).

☐ c. Attached is our check in the amount of \$180.00 in payment of the fee under 37 C.F.R. 1.17(p). Please credit or debit Dep Acct No. 14-1140 as needed to ensure consideration of the disclosed information. A duplicate copy of this paper is attached.

☐ This IDS is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check in the amount of \$180.00 to cover payment of the petition fee under 37 C.F.R. 1.17(I)(1). Please credit or debit Deposit Account No. 14-1140 as needed to ensure consideration of the disclosed information. A duplicate copy of this paper is attached.

☐ a. I hereby certify that each item of information contained in this IDS was first cited in the attached communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this IDS. 37 C.F.R. 1.97(e)(1).

☐ b. I hereby certify that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. 1.97(e)(2).

☐ Relevance of the non-English language reference(s) is discussed in the present specification.

☐ The reference(s) was/were cited in _____.

☐ A concise explanation of the relevance of the non-English language reference(s) appears in the Appendix hereto.

☐ The Examiner's attention is directed to co-pending U.S. Patent Application No. _____, filed _____, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.


☐ Copies of the references were cited by or submitted to the Office in parent Application No. _____, filed _____ and are being resubmitted herein for the Examiner's consideration. Form PTO 1449 is attached with copies of the aforementioned references.

☒ Please charge any fee associated with the filling of this paper to our Deposit Account No. 14-1140.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:



Joseph S. Presta
Reg. No. 35,329

JSP:mg
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

SERIAL NO.

4110-40

10/534,469

APPLICANT

MARGEL et al.

(Use several sheets if necessary)

FILING DATE

TC/A.U.

May 11, 2005

To be assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,103,379	8/2000	MARGEL et al.			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Brandiss et al. "Synthesis and Characterization of Self-Assembled Hydrophobic Monolayer Coatings on Silica Colloids", American Chemical Society, 1993, reprinted from Langmuir, 1993, Vol. 9, No. 5, pps. 1232-1240.
	Melamed et al. "Poly(N-vinyl α -phenylalanine) Microspheres: Synthesis, Characterization, and Use for Immobilization and Microencapsulation", Journal of Colloid and Interface Science, 241, pages 357-365, 2001.
	Horák et al. "Biologically Active Thrombin-Containing Hydrogels Based on Poly(2-hydroxyethyl methacrylate) for Endovascular Occlusion", Polymers in Medicine, 1991, Vol. XXI, No. 1-2, pages 31-40.
	Bamnlolker et al. "Dispersion Polymerization of Styrene in Polar Solvents: Effect of Reaction Parameters on Microsphere Surface Composition and Surface Properties, Size and Size Distribution, and Molecular Weight", Journal of Polymer Science: Part A: Polymer Chemistry, Vol. 34, 1857-1871, 1996, John Wiley & Sons.
	Parrado et al., "Immobilization-Stabilization of Kerase, a Serine Protease from <i>Streptomyces fradiae</i> , by Covalent Attachment to Porous Glass", Biosci. Biotech. Biochem., 59 (5), pages 906-907, 1995
	Müller et al. "Intravenously Injected Particles: Surface Properties and Interaction with Blood Proteins--The Key Determining the Organ Distribution", Scientific and Clinical Applications of Magnetic Carriers, Plenum Press, New York, 1997, pages 135-148.
	Bendikiene et al. "Stabilization of Serine Proteases by Immobilization", Stability and Stabilization of Biocatalysts, 1998, Elsevier Science B.V., pages 583-588.
	Grüttner et al., "Preparation and Characterization of Magnetic Nanospheres for In Vivo Application", Scientific and Clinical Applications of Magnetic Carriers, Plenum Press, New York, 1997, pages 53-67.
	Margel et al., "Synthesis, Characterization, and Use of New Solid and Hollow, Magnetic and Non-Magnetic, Organic-Inorganic Monodispersed Hybrid Microspheres", Scientific and Clinical Applications of Magnetic Carriers, Plenum Press, New York, 1997, pages 37-51.
	Margel et al., "Functional Nanospheres: Synthesis and Biological Applications", Recent Res. Devel. In Polymer Science, 1 (1997), pages 51-78.
	Sugitachi et al., "New Materials for Hemostasis", Progress in Artificial Organs - 1985, ISAO Press, Cleveland 1986, pps. 1020-1023.
	Liu et al., "Gold Labeling of Thrombin and Ultrastructural Studies of Thrombin-Gold Conjugate Binding by Fibrin", Analytical Biochemistry 147, 1985, pages 49-56.
	Stöber et al., "Controlled Growth of Monodisperse Silica Spheres in the Micron Size Range", Journal of Colloid and Interface Science 26, 1968, pages 62-69.

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.